Cannabinoid Receptors in Diabetic Kidney Disease

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• The endocannabinoid system (ECS), including CB1R and CB2R, is present in the kidney.
• Expression of CB1R and CB2R is altered in experimental diabetic kidney disease (DKD).

Purpose of the Study:

• To review and summarize research on the ECS's relevance in diabetic kidney disease (DKD).

Main Methods:

• Review of preclinical studies involving experimental animals and cultured kidney cells.
• Assessment of the effects of modulating CB1R and CB2R.

Main Results:

• Peripheral CB1R blockade and CB2R activation demonstrated beneficial effects in experimental DKD.
• Combined treatment targeting both CB1R and CB2R showed enhanced efficacy.
• Both CB1R and CB2R are implicated in DKD pathogenesis.

Conclusions:

• The ECS, specifically CB1R and CB2R, represents a potential therapeutic target for DKD.
• Further understanding of the ECS is required before human clinical trials can be initiated.